metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis (English Edition)
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis (English Edition) Evaluation of the relationship between atherosclerosis and Helicobacter pylori i...
Journal Information
Vol. 36. Issue 2.
Pages 51-59 (March - April 2024)
Share
Share
Download PDF
More article options
Vol. 36. Issue 2.
Pages 51-59 (March - April 2024)
Original article
Evaluation of the relationship between atherosclerosis and Helicobacter pylori infection with measurement of growth differentiation factor 15 and atherosclerosis indicators in adults with no comorbidity
Evaluación de la relación entre aterosclerosis e infección por Helicobacter pylori con medición del factor de diferenciación de crecimiento 15 e indicadores de aterosclerosis en adultos sin comorbilidad
Osman Başpinara, Ayça Elibola, Derya Koçerb, Turgut Tursem Tokmakc, Serkan Doğand, Oğuzhan Sıtkı Dizdara,
Corresponding author
osdizdar@gmail.com

Corresponding author.
a Department of Internal Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey
b Department of Medical Biochemistry, Kayseri City Training and Research Hospital, Kayseri, Turkey
c Department of Radiology, Kayseri City Training and Research Hospital, Kayseri, Turkey
d Department of Gastroenterology, Kayseri City Training and Research Hospital, Kayseri, Turkey
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Laboratory measurements and atherosclerosis indicators of patients who were Helicobacter pylori positive and negative.
Table 2. Correlation of GDF-15 and CIMT with age, laboratory measurements and atherosclerosis indicators.
Table 3. Evaluation of GDF-15 and atherosclerosis indicators according to bacterial density in endoscopic biopsy material.
Show moreShow less
Abstract
Background

The aim of this study was to investigate presence of subclinical atherosclerosis by measuring carotid intima-media thickness (CIMT) in patients with Helicobacter pylori (HP) and to assess effects of HP on atherosclerosis by evaluating markers of atherosclerosis and blood growth differentiation factor (GDF-15) levels.

Materials and methods

This cross-sectional study included 59 patients without comorbid disease who had HP and 30 healthy controls without HP in upper endoscopic biopsy. In order to assess atherosclerosis, the CIMT measurement was performed by sonography. Serum GDF-15 level was measured by ELISA method. In all patients, atherosclerosis markers were recorded. Atherogenic indices were calculated, including Castelli risk index I and II (TG/HDL-c and LDL-c/HDL-c, respectively), plasma atherogenic index (PAI; log TG/HDL-c), non-HDL-c (TH-HDL-c) and atherogenic coefficient (AC; non-HDL-HDL-c).

Results

The GDF-15 level and CIMT were significantly higher in HP-positive group when compared to HP-negative group (p0.001). There was a significant correlation between serum GDF-15 level and CIMT (r=0.445; p0.001). There was no correlation between other atherosclerosis markers and serum GDF-15 level or CIMT. The bacterial intensity on endoscopic specimen was only correlated with CIMT (p<0.001). Vitamin B12 and D levels were comparable among groups.

Conclusion

This study suggested that there was a correlation between GDF-15 level and subclinical atherosclerosis development in patients with HP. However, GDF-15 level, which was found to be elevated while atherogenic indices were normal, can be an earlier marker for subclinical atherosclerosis.

Keywords:
GDF-15
Helicobacter pylori
Atherosclerosis
Carotid intima-media thickness
Resumen
Antecedentes

El objetivo de este estudio fue investigar la presencia de aterosclerosis subclínica mediante la medición del grosor íntima-media de la carótida (GIMC) en pacientes con Helicobacter pylori y evaluar los efectos de H.pylori sobre la aterosclerosis mediante la evaluación de marcadores de aterosclerosis y de niveles de factor de diferenciación del crecimiento sanguíneo (growth differentiation factor 15 [GDF-15]).

Materiales y métodos

Este estudio transversal incluyó 59 pacientes sin enfermedad comórbida que tenían H.pylori y 30 controles sanos sin H.pylori en la biopsia endoscópica superior. Para evaluar la aterosclerosis, la medición de GIMC se realizó mediante ecografía. El nivel de GDF-15 en suero se midió mediante el método ELISA. En todos los pacientes se registraron marcadores de aterosclerosis. Se calcularon los índices aterogénicos, incluyendo el índice de riesgo de Castelli I y II (TG/cHDL y cLDL-cHDL, respectivamente), el índice aterogénico plasmático (PAI; log TG/HDL-c), no-cHDL (TH-cHDL) y el coeficiente aterogénico (no-HDL-cHDL).

Resultados

Los niveles de GDF-15 y de GIMC fueron significativamente más altos en el grupo H.pylori positivo en comparación con el grupo H.pylori negativo (p0,001). Hubo una fuerte correlación entre el nivel sérico de GDF-15 y el GIMC (r=0,445; p0,001). No hubo correlación entre otros marcadores de aterosclerosis y el nivel sérico de GDF-15 o GIMC. La intensidad bacteriana en la muestra endoscópica solo se correlacionó con GIMC (p0,001). Los niveles de vitaminaB12 y de vitaminaD fueron comparables entre los grupos.

Conclusión

Este estudio sugirió que había una correlación entre el nivel de GDF-15 y el desarrollo de aterosclerosis subclínica en pacientes con H.pylori. Sin embargo, el nivel de GDF-15, que se encontró elevado mientras que los índices aterogénicos eran normales, puede ser un marcador temprano de aterosclerosis subclínica.

Palabras clave:
GDF-15
Helicobacter pylori
Aterosclerosis
Grosor íntima-media carotídeo

Article

These are the options to access the full texts of the publication Clínica e Investigación en Arteriosclerosis (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Clínica e Investigación en Arteriosclerosis (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos